Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity

Heredia, Alonso; Gaywee, Jariyanart; Oldach, David; Drusano, George L.; Redfield, Robert

doi:10.1097/01.pas.0000213299.11649.101

Cited by 42 publications

(44 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most cases, subjects continued their pre-transplant regimen in the posttransplant period. Referring health care providers were advised of the unknown implications of in vitro antiretroviral antagonism between mycophenolate mofetil and the thymidine analog nucleoside reverse transcriptase inhibitors, zidovudine and stavudine (18). In three cases, the provider modified the HAART regimen prior to transplant to replace these agents.…”

Section: Interventionsmentioning

confidence: 99%

HIV-Infected Liver and Kidney Transplant Recipients: 1- and 3-Year Outcomes

Roland

Barin

Carlson

et al. 2008

American Journal of Transplantation

223

199

View full text Add to dashboard Cite

Improvements in human immunodeficiency virus (HIV)-associated mortality make it difficult to deny transplantation based upon futility. Outcomes in the current management era are unknown. This is a prospective series of liver or kidney transplant recipients with stable HIV disease. Eleven liver and 18 kidney transplant recipients were followed for a median of 3.4 years (IQR [interquartile range] 2.9-4.9). One-and 3-year liver recipients' survival was 91% and 64%, respectively; kidney recipients' survival was 94%. One-and 3-year liver graft survival was 82% and 64%, respectively; kidney graft survival was 83%. Kidney patient and graft survival were similar to the general transplant population, while liver survival was similar to the older population, based on 1999-2004 transplants in the national database. CD4+ T-cell counts and HIV RNA levels were stable; and there were two opportunistic infections (OI). The 1-and 3-year cumulative incidence (95% confidence intervals [CI]) of rejection episodes for kidney recipients was 52% (28-75%) and 70% (48-92%), respectively. Two-thirds of hepatitis C virus (HCV)-infected patients, but no patient with hepatitis B virus (HBV) infection, recurred. Good transplant and HIV-related outcomes among kidney transplant recipients, and reasonable outcomes among liver recipients suggest that transplantation is an option for selected HIV-infected patients cared for at centers with adequate expertise.

show abstract

Section: Interventionsmentioning

confidence: 99%

HIV-Infected Liver and Kidney Transplant Recipients: 1- and 3-Year Outcomes

Roland

Barin

Carlson

et al. 2008

American Journal of Transplantation

223

199

View full text Add to dashboard Cite

show abstract

“…Starzl et al [36]in the pre-HAART era reported that HIV-infected transplant recipients who were on cyclosporine-based immunosuppressive regimen had a better survival. Recent reports have suggested that even mycophenolate mofetil, another common drug used after transplantation, may potentiate the antiretroviral effect of commonly used HIV drugs [38, 39]. Although the concern about potential interactions between protease inhibitors and calcineurin inhibitor is real, this can be resolved by monitoring drug levels and pharmacokinetic studies [40].…”

Section: Renal Replacement Therapymentioning

confidence: 99%

Dialyzing a Patient with Human Immunodeficiency Virus Infection: What a Nephrologist Needs to Know

Mandayam

Ahuja

2004

Am J Nephrol

View full text Add to dashboard Cite

The percentage of dialysis centers that have reported dialyzing human immunodeficiency virus (HIV)-infected patients increased from 11% in 1985 to 37% in 2000. Being primary care physicians for the dialysis patients, nephrologists are frequently confronted with the management of HIV-infected dialysis patients especially in urban centers. The aims of the present review are to discuss issues that are unique to HIV infection and end-stage renal disease, and to provide dialysis caretakers with sufficient information to help them optimize care and improve outcomes of these patients. Issues related to the choice of renal replacement therapy, vascular access, management of anemia, vaccination, and antiretroviral therapies are discussed in detail.

show abstract

“…In vivo MPA alone is not effective against HSV, but it has been shown to enhance the anti-HSV activities of acyclovir, gancyclovir and pencyclovir in experimental animals 183 . Interestingly, MPA has also been shown to synergize with antiretroviral drugs 184,185 as well as with cyclosporin A and IFN-a in HCV inhibition 181 . However, due to its mode of action, the long-term use of MPA might lead to development of drug resistance as it was previously shown for Sindbis virus 186 .…”

Section: Bsas Derived From Fungi: Cyclosporine Statins and Mycophenomentioning

confidence: 99%

Antiviral drug discovery: broad-spectrum drugs from nature

et al. 2015

View full text Add to dashboard Cite

, but cannot be converted to PDF. You must view these files (e.g. movies) online.Scheme 1_(structures 1-5)_named.cdx Scheme 2_(structures 6-8)_named.cdx Scheme 3_(structure 9)_named.cdx Scheme 4_(structure 10)_named.cdx Scheme 5_ (structures 11-12) The development of drugs with broad-spectrum antiviral activities is a long pursued goal in drug discovery. It has been shown that blocking co-opted host-factors abrogates the replication of many viruses, yet the development of such host-targeting drugs has been met with skepticism mainly due to toxicity issues and poor translation to in vivo models. With the advent of new and more powerful screening assays and prediction tools, the idea of a drug that can efficiently treat a wide range of viral infections by blocking specific host functions has rebloomed. Here we critically review the state-of-the-art in broad-spectrum antiviral drug discovery. We discuss putative targets and treatment strategies, taking particular focus on natural products as promising starting points for antiviral lead development.

show abstract

Abacavir and Mycophenolic Acid, an Inhibitor of Inosine Monophosphate Dehydrogenase, Have Profound and Synergistic Anti-HIV Activity

Cited by 42 publications

References 29 publications

HIV-Infected Liver and Kidney Transplant Recipients: 1- and 3-Year Outcomes

HIV-Infected Liver and Kidney Transplant Recipients: 1- and 3-Year Outcomes

Dialyzing a Patient with Human Immunodeficiency Virus Infection: What a Nephrologist Needs to Know

Antiviral drug discovery: broad-spectrum drugs from nature

Contact Info

Product

Resources

About